News headlines about Luminex (NASDAQ:LMNX) have trended somewhat positive on Sunday, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Luminex earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 46.2019914798146 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Luminex (NASDAQ:LMNX) opened at $21.23 on Friday. Luminex has a twelve month low of $17.68 and a twelve month high of $22.42. The firm has a market cap of $941.00, a P/E ratio of 36.83, a P/E/G ratio of 2.68 and a beta of 0.19.

Luminex (NASDAQ:LMNX) last announced its quarterly earnings data on Monday, October 30th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.06. Luminex had a net margin of 9.52% and a return on equity of 6.01%. The business had revenue of $74.14 million for the quarter, compared to analyst estimates of $74.38 million. During the same period in the prior year, the business posted $0.21 earnings per share. Luminex’s revenue was up 4.1% compared to the same quarter last year. equities research analysts forecast that Luminex will post 0.49 EPS for the current fiscal year.

A number of brokerages have recently issued reports on LMNX. BidaskClub lowered shares of Luminex from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 9th. ValuEngine upgraded shares of Luminex from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Zacks Investment Research upgraded shares of Luminex from a “hold” rating to a “strong-buy” rating and set a $22.00 target price on the stock in a research report on Thursday, August 24th. TheStreet upgraded shares of Luminex from a “c+” rating to a “b-” rating in a report on Wednesday, November 1st. Finally, Jefferies Group restated a “hold” rating and issued a $21.00 price objective on shares of Luminex in a report on Friday, October 20th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a strong buy rating to the stock. Luminex presently has an average rating of “Hold” and an average target price of $20.00.

In related news, Director G Walter Loewenbaum II sold 50,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $21.79, for a total value of $1,089,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 6.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Luminex (LMNX) Earns Daily Media Impact Rating of 0.11” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/12/03/luminex-lmnx-earns-daily-media-impact-rating-of-0-11.html.

About Luminex

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Insider Buying and Selling by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Stock Ratings for Luminex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related stocks with our FREE daily email newsletter.